Compare LBTYA & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBTYA | MMED |
|---|---|---|
| Founded | 2004 | 1983 |
| Country | Bermuda | United States |
| Employees | 6636 | 2800 |
| Industry | Cable & Other Pay Television Services | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.3B |
| IPO Year | N/A | 2026 |
| Metric | LBTYA | MMED |
|---|---|---|
| Price | $10.01 | $17.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $13.72 | ★ $22.56 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 05-01-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.41 | $15.99 |
| Revenue Next Year | $3.03 | $10.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.43 | $10.65 |
| 52 Week High | $13.52 | $17.86 |
| Indicator | LBTYA | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 67.72 |
| Support Level | N/A | $14.70 |
| Resistance Level | $11.56 | N/A |
| Average True Range (ATR) | 0.32 | 0.92 |
| MACD | -0.05 | 0.08 |
| Stochastic Oscillator | 36.19 | 91.33 |
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.